- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573881
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK) (#HOPE4LIVER)
January 11, 2024 updated by: HistoSonics, Inc.
This trial is a single arm, non-randomized prospective trial.
The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This trial is a single arm, non-randomized, multicenter, prospective trial.
Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success.
Subjects will then be followed for 30 days.
Additionally, subjects will be evaluated at 6 months and followed annually for up to five (5) years post-index procedure.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zoe Secord
- Phone Number: 612-474-2493
- Email: zoe.secord@histosonics.com
Study Contact Backup
- Name: Christine Sullivan
- Phone Number: 612-474-2493
- Email: christine.sullivan@histosonics.com
Study Locations
-
-
-
Braunschweig, Germany
- Städtisches Klinikum Braunschweig gGmbH
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg Klinik für Radiologie und Nuklearmedizin
-
-
-
-
-
Milano, Italy
- Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.
-
-
-
-
-
Barcelona, Spain
- Vall d'Hebron
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
Newcastle, United Kingdom, NE7 7DN
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is ≥18 years of age
- Subject has signed the Ethics Committee (EC) or Institutional Review Board (IRB) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments
- Subject is diagnosed with hepatocellular carcinoma (HCC) or liver metastases (mets) from other primary cancers
- Subject is able to undergo general anesthesia
- Subject has a Child-Pugh Score of A or B (up to B8)
- Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2 at baseline screening
Subject meets the following functional criteria, ≤7 days prior to the index-procedure:
- Liver function: Alanine transaminase (ALT) and Aspartate transaminase (AST) <2.5x upper limit of normal (ULN) and bilirubin <2.5x ULN, and
- Renal function: serum creatinine <2x ULN, and
- Hematologic function: neutrophil count >1.0 x 10^9/L and platelet >50 x 10^9/L
- Subject has an International Normalized Ratio (INR) score of <2.0 , ≤7 days prior to the index procedure
- Subject has not responded to and/or has relapsed and/or is intolerant of other available therapies including locoregional therapies, chemotherapy, immunotherapy and targeted therapies.
- The tumor(s) selected for histotripsy treatment must be ≤3 cm in longest diameter
- Subject has an adequate acoustic window to visualize targeted tumor(s) using ultrasound imaging
- Subject has a maximum of three (3) tumors to be treated with histotripsy during the index procedure, regardless of how many tumors the subject has.
Exclusion Criteria:
- Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period
- Subject is enrolled in another investigational trial and/or is taking investigational medication or treated with an investigational device ≤30-days prior to index procedure
- In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics System
- Subject has a serum creatinine >2.0 mg/dL or estimated glomerular filtration rate (EGFR) <30, unless on dialysis
- Subject has major surgical procedure or significant traumatic injury ≤2 weeks prior to the index procedure or not fully recovered from side effects/complications of such procedure or trauma
- Subject has not recovered to common terminology criteria for adverse events (CTCAE) grade 1 or better from any adverse effects (except alopecia) related to previous anti-cancer therapy
- Subject has a history of, or suspected to have, bleeding disorders that are uncorrectable
- Subject has a coagulopathy that is uncorrectable
- Subject has a planned cancer treatment (e.g. resection, chemotherapy, etc.) from the index-procedure date and prior to completion of the 30-day follow-up visit
- Subject has previous treatment with bevacizumab that has not been discontinued >40 days prior to the planned index-procedure date
- Subject has planned bevacizumab treatment prior to completion of the 30-day follow-up visit
- Subject has previous treatments with chemotherapy and/or radiotherapy that has not been discontinued ≥2 weeks prior to the planned index-procedure date or has not recovered from related toxicity
- Subject has previous treatment with immunotherapies that has not been discontinued ≥4 weeks prior to the index-procedure or has not recovered from related toxicity
- Subject has a life expectancy less than six (<6) months
- In the opinion of the Investigator, histotripsy is not a treatment option for the subject
- Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol
- Subjects' tumor(s) is not treatable by the System's working ranges (refer to User Manual)
- Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated
- Subjects' targeted tumor(s) has/have had prior locoregional therapy (e.g. ablation, embolization, radiation)
- Subject is eligible for surgical resection
- Targeted tumor(s) treatment volume overlaps a non-targeted tumor visible via imaging
- The targeted tumor(s) is not clearly visible with diagnostic ultrasound and computed tomography (CT) or magnetic resonance (MR) imaging
- The targeted tumor(s) is located in liver segment 1
- The Planned Treatment Volume intended to cover the targeted tumor includes or encompasses any portion of the main portal vein, common hepatic duct, common bile duct, gallbladder or stomach/bowel
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HistoSonics System
|
The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy: Technical Success
Time Frame: ≤36 hours post-index procedure
|
Technical success, defined as the treatment volume/treatment dimensions being greater than or equal to the targeted tumor, and with complete tumor coverage, via computed tomography (CT) or magnetic resonance (MR) imaging.
[Core Laboratory Adjudicated]
|
≤36 hours post-index procedure
|
Primary Safety: Procedure-Related Major Complications
Time Frame: 30 days post-index procedure
|
Number of index procedure related major complications, including device-related events defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicities observed up to 30-days post index-procedure.
[Clinical Events Committee Adjudicated]
|
30 days post-index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy: Technique Efficacy
Time Frame: 30 days post-index procedure
|
Technique efficacy, defined as the lack of a nodular or mass-like area of enhancement within or along the edge of the treatment volume assessed via CT or MR imaging at 30-days post-procedure.
[Core Laboratory Adjudicated]
|
30 days post-index procedure
|
Secondary Safety: All Adverse Events
Time Frame: 30 days post-index procedure
|
Number of adverse events (serious and non-serious) reported within 30 days post-index procedure.
[Clinical Events Committee Adjudicated]
|
30 days post-index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Luigi A Solbiati, MD, Humanitas Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 4, 2021
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
September 28, 2020
First Submitted That Met QC Criteria
September 28, 2020
First Posted (Actual)
October 5, 2020
Study Record Updates
Last Update Posted (Actual)
January 16, 2024
Last Update Submitted That Met QC Criteria
January 11, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP1473
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasms
-
Ethicon, Inc.Terminated
-
Ethicon, Inc.RecruitingLiver Cancer | Cancer of the Liver | Neoplasms, LiverUnited Kingdom, United States, Netherlands, Singapore, France, Germany, China, Korea, Republic of
-
Ewha Womans University Mokdong HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Chonnam National... and other collaboratorsUnknown
-
China Medical University HospitalActive, not recruitingLiver Transplant, Liver Cancer, ImmunosuppressantTaiwan
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedLiver Tumor | Evidence of Liver TransplantationChina
-
Tel-Aviv Sourasky Medical CenterCompletedPrimary Liver Tumor, Metastatic LiverIsrael
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Medical University of WarsawJagiellonian University; Medical University of Lublin; Medical University of... and other collaboratorsRecruiting
-
Beijing Immunochina Medical Science & Technology...Recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
Clinical Trials on HistoSonics System
-
HistoSonics, Inc.RecruitingKidney Cancer | Renal Cancer | Tumor | Tumor, Solid | Tumor, BenignUnited States
-
HistoSonics, Inc.RecruitingKidney Cancer | Kidney Neoplasms | Renal Cancer | Tumor | Tumor, Solid | Tumor, BenignUnited Kingdom
-
HistoSonics, Inc.Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver MetastasesUnited States
-
HistoSonics, Inc.Not yet recruitingThe HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy (GANNON)Pancreatic Cancer | Pancreas Cancer | Adenocarcinoma of the Pancreas | Tumor of PancreasSpain
-
HistoSonics, Inc.WithdrawnBenign Prostatic Hyperplasia (BPH)
-
HistoSonics, Inc.TerminatedSafety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)Benign Prostatic Hyperplasia (BPH)United States
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States